Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (241-250 of 578) with videos related to

Pageof 58
Sort By:
Gynecologic Oncology|July 13, 2021
Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteriaJolien Haesen, Rawand Salihi, Toon Van Gorp, et al.
European Radiology|December 11, 2013
Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CTKatrijn Michielsen, Ignace Vergote, Katya Op de Beeck, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2026
Pre-operative assessment in International Federation of Gynaecology and Obstetrics-2009 stage IB2 to IIB cervical cancer: role of delayed gadolinium-enhanced magnetic resonance imaging after neoadjuvant chemotherapyVincent Vandecaveye, Marie-Sofie Walgraeve, Frederik De Keyzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2008
Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndromeLeilani Morales, Steven Pans, Kilian Verschueren, et al.
Oncotargets and Therapy|September 24, 2014
HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD ConsortiumElena Ioana Braicu, Hrvoje Luketina, Rolf Richter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2007
Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumorsDirk Timmerman, Ben Van Calster, Davor Jurkovic, et al.
Cancers|December 10, 2021
Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian CancerChristine De Bruyn, Jolien Ceusters, Chiara Landolfo, et al.
The Lancet. Oncology|March 15, 2016
Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomasWouter Froyman, Chiara Landolfo, Frédéric Amant, et al.
Cancers|June 2, 2021
The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD ConsortiumEva Obermayr, Angelika Reiner, Burkhard Brandt, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2013
Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trialHannah S van Meurs, Parvin Tajik, Michel H P Hof, et al.
Pageof 58

Showing results (241-250 of 578) with videos related to

Sort By:
Pageof 58
Gynecologic Oncology|July 13, 2021
Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteriaJolien Haesen, Rawand Salihi, Toon Van Gorp, et al.
European Radiology|December 11, 2013
Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CTKatrijn Michielsen, Ignace Vergote, Katya Op de Beeck, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2026
Pre-operative assessment in International Federation of Gynaecology and Obstetrics-2009 stage IB2 to IIB cervical cancer: role of delayed gadolinium-enhanced magnetic resonance imaging after neoadjuvant chemotherapyVincent Vandecaveye, Marie-Sofie Walgraeve, Frederik De Keyzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2008
Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndromeLeilani Morales, Steven Pans, Kilian Verschueren, et al.
Oncotargets and Therapy|September 24, 2014
HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD ConsortiumElena Ioana Braicu, Hrvoje Luketina, Rolf Richter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2007
Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumorsDirk Timmerman, Ben Van Calster, Davor Jurkovic, et al.
Cancers|December 10, 2021
Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian CancerChristine De Bruyn, Jolien Ceusters, Chiara Landolfo, et al.
The Lancet. Oncology|March 15, 2016
Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomasWouter Froyman, Chiara Landolfo, Frédéric Amant, et al.
Cancers|June 2, 2021
The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD ConsortiumEva Obermayr, Angelika Reiner, Burkhard Brandt, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2013
Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trialHannah S van Meurs, Parvin Tajik, Michel H P Hof, et al.
Pageof 58